Japan, December 14, 2009 – Astellas Pharma Inc. (Headquarters: Tokyo, President and CEO: Masafumi Nogimori, hereinafter called the “the Company”) announced that it completed acquisition of its treasury stock, which was resolved by its Board of Directors on November 5, 2009, pursuant to Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.
Particulars
1. Class of shares acquired: Common stock of the Company
2. Total number of shares acquired: 8.2 million shares
3. Aggregate amount of acquisition cost: 26,961,398,000yen
4. Period of acquisition: From November 9, 2009 to December 11,
2009
(Reference)
Details of the resolution at the meeting of the Board of Directors
(announced on November 5, 2009)
- Class of shares to be acquired: Common stock of the Company
- Total number of shares to be acquired: 8.2 million shares (Maximum)
(The percentage compared to the total number of shares
outstanding:1.74%)
- Aggregate amount of acquisition cost: 30 billion yen (Maximum)
- Period of acquisition: From November 9, 2009 to December 11, 2009
######
